Effectiveness of conservative treatment of Peyronie's disease
Abstract
The article is devoted to the effectiveness of conservative treatment of Peyronie's disease. As a result, it was found that the drug Potaba affects Peyronie's plaque. The drug can slightly improve the existing curvature of the penis, there is a significant protective effect, especially if the effect is pronounced with a short course of the disease. Potassium para aminobenzoate is useful in stabilizing Peyronie's disease and is needed to prevent the progression of penile curvature, which "stops" the process. The plaque does not increase, and the angle of curvature does not increase. The stabilization stage comes faster and with fewer consequences. Group B with Peyronie's disease who received a combination of oral medications (vitamin A, E) and intralesional injections of kenalog and dexamethasone showed a significant improvement in penile curvature, pain, erectile function, and patient satisfaction. These data support the potential efficacy of this approach in treating the symptoms of Peyronie's disease. Further research, including randomized controlled trials and larger sample sizes, is needed to confirm these results and establish the optimal treatment protocol for patients with this complex condition. Those who received a combination of oral preparations (vitamins A, E), intralesional injections of kenalog and dexamethasone, and extracorporeal shock wave therapy increase the effectiveness of treatment up to 55.6%. After the termination of the course of treatment, if the curvature is only cosmetic in nature and does not interfere with sexual intercourse, and does not violate the erection, then the operation is not necessary. Unfortunately, no guarantees can be made about preventing the future progression of the disease. The results of the study indicate the effect of Potaba on Peyronie's plaque. The drug can slightly improve the existing curvature of the penis, there is a significant protective effect, especially if the effect is pronounced with a short course of the disease. Potassium para aminobenzoate is useful in stabilizing Peyronie's disease and is needed to prevent the progression of penile curvature, which "stops" the process. The plaque does not increase, and the angle of curvature does not increase. The stabilization stage comes faster and with fewer consequences.
References
Levin LA. Peyronie's disease: a clinical management guide. Totova, NJ: Humana Press; 2007.
Mulhall J. P. et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening //The Journal of urology. - 2004. - V. 171. - No. 6 Part 1. - P. 2350-2353.
Levin L.A., Larsen S.M. Intracavernous injection therapy: analysis of results and complications. Journal of Urology. 1990;143(6):1138-1141.
Gonzalez-Cadavid NF, Reifer J. Mechanisms of the disease: a new look at the cellular and molecular pathology of Peyronie's disease. Nature Clinical practice Urology. 2005;2(6):291-297.
Accus E, Carrier S, Rehman J, et al. Is colchicine effective for Peyronie's disease? Pilot study. Urology. 1994;43(5):679-684.
Palmer LS, Palmer JS, Franco I, et al. Improvement in erectile function in response to transurethral alprostadil after a second hyaluronic acid copolymer injection in men with Peyronie's disease and erectile dysfunction. Journal of Urology. 2001;165(3):825-827.
